Thursday, February 08, 2007

27 companies net €98.4 million in funding
More Details?




New profiles

Connect Scotland
Science Warehouse
ProVision
David Sykes
Anna Krawiec

Add your Profile


European ISV Convention 2007
Network Convergence
The Swiss Tech Tour

Submit your event(s)!


On the move

New ReVolt Technology BoD member
Eqvitec strengthens Swedish team
AM-Pharma appoints Bart Wuurman as CEO

Career move?


Created by: Tornado Staff


Big Bang in the Benelux

Belgian venture capitalist (VC) Big Bang Ventures is showing a huge boost in activity, having announced three investments in the Benelux in the past week alone. Together with Wellington Partners and Partech International the company invested €7 million in a follow-up round for Q-layer, a Belgian provider of datacenter solutions. Big Bang co-led a non-disclosed Series A funding round in 24access, a Dutch developer of mobile applications. The other lead investor was Dutch early-stage VC Solid Ventures, which has also picked up speed with 3 investments announced in the past 3 weeks. On the same day as the 24access deal, Big Bang and Solid also disclosed their joint investment in Dutch Avinity Systems' first-round funding. Avinity specializes in solutions for digital television.

Big Bang Ventures of Belgium was formed in 2000 and, according to the company's Managing Partner, has "been through it all" in the past years. Frank Maene said: "2000 and 2001 were overheated. In 2002 to 2005 we were in the dark middle ages. In 2006 things picked up again. For example, there is money available for investment, customers are buying and there are some good technologies sprouting up." Maene is currently meeting with numerous entrepreneurs who have been working without funding and salaries for the past few years to develop their ideas. "Now they have proof of concept when they approach VCs to help them take the next step."


Venture capital activity in Belgium and The Netherlands showed different trends in the last years. Belgium was in a real slump in 2004 and 2005, with investments at an annual average of around €50 million. The Netherlands showed a steady increase from €112 million in 2004 via €175 million in 2005 to €188 million in 2006. However, Belgian companies hit the jackpot in 2006 and collected €185 million – almost the same amount raised across the border. The upswing in capital invested is the result of recent successful fundraising efforts by some Belgian investors. Nevertheless, deal activity remains modest in Belgium (18 in 2006) compared to The Netherlands (42 deals in 2006). Frank Maene confirms this, stating: “Belgium has fewer deals, but bigger rounds.”

In both countries, Biotechnology & Healthcare topped the sector rankings, collecting 45% of the total technology investment in Belgium and 49% in The Netherlands. Computers & Electronics took second place (approx. 23%), followed by Software (approx. 14%). Dutch early-stage investment respresented almost 40% of the total invested in 2006, partly stimulated by the seed funds allocated by the government-related TechnoPartner initiative. In Belgium, just 20% of the invested funds concerned early-stage deals.


Creandum closes second fund at €82 million
Floppies are Dead… Long Live Floppies
immatics receives €40 million in second round of funding
Tessera Technologies acquired Eyesquad
Xiam Technologies sees record revenue growth with major new Operator deal
Over 23 million Realeyes3D handwritten messaging enabled camera phones in use worldwide
Launch of AXONIA Partners, a financial advisory boutique
AppGate implements web filter for Windows Mobile phones
Two Scottish mobile games developers in UK Top 50
DN Capital leads investment in Digital Railroad
Funds advised by Apax Partners and TPG announce the sale of Tim Hellas to Weather Investments
Synchronica brings mobile eMail to mass market with Push IMAP and SyncML
National Semiconductor acquires data converter developer Xignal Technologies
Cilian awarded BMBF grant
New premises for Ilika expansion
Helping to grow a flourishing cleantech industry in Germany with a natural center in Munich
AstraZeneca acquires Arrow Therapeutics to broaden anti-infective capabilities
Algeta applies for listing on the Oslo Stock Exchange


Copyright © 2004-2010 Test Publishing Ltd. All rights reserved.
Subscribe here. Unsubscribe here.